Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.

Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy

Open access

Abstract

ObjectiveTo prospectively evaluate safety and efficacy of brain-responsive neurostimulation in adults with medically intractable focal onset seizures (FOS) over 9 years. MethodsAdults treated with brain-responsive neurostimulation in 2-year feasibility or randomized controlled trials were enrolled in a long-term prospective open label trial (LTT) to assess safety, efficacy, and quality of life (QOL) over an additional 7 years. Safety was assessed as adverse events (AEs), efficacy as median percent change in seizure frequency and responder rate, and QOL with the Quality of Life in Epilepsy (QOLIE-89) inventory. ResultsOf 256 patients treated in the initial trials, 230 participated in the LTT. At 9 years, the median percent reduction in seizure frequency was 75% (p < 0.0001, Wilcoxon signed rank), responder rate was 73%, and 35% had a ≥90% reduction in seizure frequency. We found that 18.4% (47 of 256) experienced ≥1 year of seizure freedom, with 62% (29 of 47) seizure-free at the last follow-up and an average seizure-free period of 3.2 years (range 1.04–9.6 years). Overall QOL and epilepsy-targeted and cognitive domains of QOLIE-89 remained significantly improved (p < 0.05). There were no serious AEs related to stimulation, and the sudden unexplained death in epilepsy (SUDEP) rate was significantly lower than predefined comparators (p < 0.05, 1-tailed χ2). ConclusionsAdjunctive brain-responsive neurostimulation provides significant and sustained reductions in the frequency of FOS with improved QOL. Stimulation was well tolerated; implantation-related AEs were typical of other neurostimulation devices; and SUDEP rates were low. Classification of evidenceThis study provides Class IV evidence that brain-responsive neurostimulation significantly reduces focal seizures with acceptable safety over 9 years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000010154

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 RNS System Left, RNS neurostimulator and NeuroPace cortical strip and depth leads. Top right, record of the number of electrographic events detected by the neurostimulator over time for an individual patient. Bottom right, snapshots of electrographic activity recorded by the RNS System for an individual patient. Copyright © 2020 NeuroPace, Inc.
Figure 1 RNS System Left, RNS neurostimulator and NeuroPace cortical strip and depth leads. Top right, record of the number of electrographic events detected by the neurostimulator over time for an individual patient. Bottom right, snapshots of electrographic activity recorded by the RNS System for an individual patient. Copyright © 2020 NeuroPace, Inc.CC BY-NC-ND · PubMed Central
Figure 2 RNS System studies, participant accountability aFeasibility study: 6 participants discontinued before completing the study; 2 participants completed the study but elected not to enroll in the long-term treatment (LTT) study. Thus, 57 participants in the feasibility study enrolled in the LTT study. bPivotal study: 16 participants discontinued before completing the study; 4 participants completed the study but elected not to enroll in the LTT study. Two participants who discontinued early were granted waivers and were allowed to enroll, resulting in 173 pivotal participants enrolling into LTT. A total of 230 participants chose to enroll in the LTT study, and 162 participants completed the study. cReasons for early withdrawal from the LTT study included the following: chose not to replace neurostimulator (n = 20); to pursue other treatment options (n = 10); insufficient efficacy (n = 8); study noncompliance (n = 7); and to receive medical care at a nonstudy center (n = 5).
Figure 2 RNS System studies, participant accountability aFeasibility study: 6 participants discontinued before completing the study; 2 participants completed the study but elected not to enroll in the long-term treatment (LTT) study. Thus, 57 participants in the feasibility study enrolled in the LTT study. bPivotal study: 16 participants discontinued before completing the study; 4 participants completed the study but elected not to enroll in the LTT study. Two participants who discontinued early were granted waivers and were allowed to enroll, resulting in 173 pivotal participants enrolling into LTT. A total of 230 participants chose to enroll in the LTT study, and 162 participants completed the study. cReasons for early withdrawal from the LTT study included the following: chose not to replace neurostimulator (n = 20); to pursue other treatment options (n = 10); insufficient efficacy (n = 8); study noncompliance (n = 7); and to receive medical care at a nonstudy center (n = 5).CC BY-NC-ND · PubMed Central
Figure 3 RNS System long term clinical response Plot showing the median percent reduction ± IQR in seizure frequency for the last 6 months of each year in the long-term treatment study (years 3 through 9 of treatment) compared to baseline for the 91-day minimum diary requirement population, the constant cohort population, and the last observation carried forward (LOCF) population. (A) Median percent reduction ± interquartile range (IQR) over time. (B) Individual changes in clinical seizure frequency. Changes in clinical seizure frequency during the last 6 months of follow-up before the year 9 visit for each participant who had at least 91 days of seizure diary data. Negative values indicate a seizure frequency reduction compared with baseline. (C) Bar graph showing the percent of all participants (All) and participants with onsets in the mesial temporal lobe (MTL) or neocortex (Neo) with at least 1 period of seizure freedom lasting at least 3, 6, and 12 months.
Figure 3 RNS System long term clinical response Plot showing the median percent reduction ± IQR in seizure frequency for the last 6 months of each year in the long-term treatment study (years 3 through 9 of treatment) compared to baseline for the 91-day minimum diary requirement population, the constant cohort population, and the last observation carried forward (LOCF) population. (A) Median percent reduction ± interquartile range (IQR) over time. (B) Individual changes in clinical seizure frequency. Changes in clinical seizure frequency during the last 6 months of follow-up before the year 9 visit for each participant who had at least 91 days of seizure diary data. Negative values indicate a seizure frequency reduction compared with baseline. (C) Bar graph showing the percent of all participants (All) and participants with onsets in the mesial temporal lobe (MTL) or neocortex (Neo) with at least 1 period of seizure freedom lasting at least 3, 6, and 12 months.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. RNS System User Manual (RNS-300M). Mountain View: NeuroPace, Inc; 2018.

Cited by

See all 491

Metadata

Authors
Nair, D. R., Laxer, K. D., Weber, P. B., Murro, A. M., Park, Y. D., Barkley, G. L., Smith, B. J., Gwinn, R. P., Doherty, M. J., Noe, K. H., Zimmerman, R. S., Bergey, G. K., Anderson, W. S., Heck, C., Liu, C. Y., Lee, R. W., Sadler, T., Duckrow, R. B., Hirsch, L. J., Wharen, R. E., Tatum, W., Srinivasan, S., McKhann, G. M., Agostini, M. A., Alexopoulos, A. V., Jobst, B. C., Roberts, D. W., Salanova, V., Witt, T. C., Cash, S. S., Cole, A. J., Worrell, G. A., Lundstrom, B. N., Edwards, J. C., Halford, J. J., Spencer, D. C., Ernst, L., Skidmore, C. T., Sperling, M. R., Miller, I., Geller, E. B., Berg, M. J., Fessler, A. J., Rutecki, P., Goldman, A. M., Mizrahi, E. M., Gross, R. E., Shields, D. C., Schwartz, T. H., Labar, D. R., Fountain, N. B., Elias, W. J., Olejniczak, P. W., Villemarette-Pittman, N. R., Eisenschenk, S., Roper, S. N., Boggs, J. G., Courtney, T. A., Sun, F. T., Seale, C. G., Miller, K. L., Skarpaas, T. L., Morrell, M. J., & Study, O. B. O. T. R. S. L.
Affiliations
Cleveland Clinic (US)
Corresponding author
Morrell, Martha J.
Venue
Neurology
Published
2020-09
Volume
95
Issue
9
Pages
e1244-e1256
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3044132865
Cited by
490
References
49
Citations by year
2026: 65 · 2025: 100 · 2024: 87 · 2023: 93 · 2022: 84 · 2021: 45 · 2020: 15
FWCI
43.23
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Neurology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
  • National Science Foundation
  • U.S. Department of Defense
  • American Epilepsy Society
  • Epilepsy Foundation
  • Citizens United for Research in Epilepsy
  • Pfizer
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Yale University
  • Biogen
  • Emory University
  • George Washington University
  • Wake Forest University
  • Cleveland Clinic
  • Cleveland Clinic Foundation
  • Johns Hopkins University
  • University of Rochester
  • Dartmouth College
  • Boston Scientific Corporation
  • Thomas Jefferson University
  • Rush University
  • University of South Carolina
  • Sunovion
  • Dravet Syndrome Foundation
  • DUSA Pharmaceuticals
  • Augusta University
  • Zogenix
  • Ultragenyx Pharmaceutical
  • GW Pharmaceuticals
  • Acorda Therapeutics
  • Sage Therapeutics
  • Adamas Pharmaceuticals
  • Boston Pharmaceuticals
  • SK Life Science
  • NeuroPace
  • Upsher-Smith
  • Martin Family Foundation
  • University of Oxford
  • Carl Zeiss Meditec AG
  • Eisai
  • H. Lundbeck A/S
  • Epilepsy Society
  • National Institutes of Health (UL1TR001863)
  • Centers for Disease Control and Prevention
  • U.S. Food and Drug Administration
  • Genentech
  • St. Jude Medical
  • Weill Cornell Medical College
  • School of Medicine, Emory University
  • Advanced Research Projects Agency
  • Audrey and Theodor Geisel School of Medicine at Dartmouth
  • Medical Center, University of Rochester
  • School of Medicine, Indiana University
  • UCB US
  • Greenwich Biosciences
  • National Cancer Institute (P30CA023108)
  • National Center for Advancing Translational Sciences
  • UCB Pharma
  • Medical Research and Materiel Command
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
focal epilepsy, drug-resistant epilepsy, focal seizures, seizure frequency reduction, seizure freedom, quality of life, sudden unexpected death in epilepsy, long-term safety, adjunctive therapy
MeSH terms
Drug Resistant Epilepsy, Sudden Unexpected Death in Epilepsy, Adolescent, Adult, Aged, Depressive Disorder, Electric Stimulation Therapy, Epilepsies, Partial, Female, Follow-Up Studies, Humans, Male, Memory Disorders, Middle Aged, Prospective Studies, Quality of Life, Status Epilepticus, Suicide, Randomized Controlled Trials as Topic, Prosthesis-Related Infections, Treatment Outcome, Intracranial Hemorrhages, Young Adult, Implantable Neurostimulators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. https://app.cochat.ai/papers/10.1212/wnl.0000000000010154
The paper
Nair, D. R., Laxer, K. D., Weber, P. B., Murro, A. M., Park, Y. D., Barkley, G. L., Smith, B. J., Gwinn, R. P., Doherty, M. J., Noe, K. H., Zimmerman, R. S., Bergey, G. K., Anderson, W. S., Heck, C., Liu, C. Y., Lee, R. W., Sadler, T., Duckrow, R. B., Hirsch, L. J., . . . Study, O. B. O. T. R. S. L. (2020). Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology. https://doi.org/10.1212/wnl.0000000000010154

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.